- Home
- LNT vs UTHR Comparison
LNT vs UTHR Comparison
Compare LNT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- UTHR
- Stock Information
- Founded
- LNT 1917
- UTHR 1996
- Country
- LNT United States
- UTHR United States
- Employees
- LNT N/A
- UTHR N/A
- Industry
- LNT Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- LNT Utilities
- UTHR Health Care
- Exchange
- LNT Nasdaq
- UTHR Nasdaq
- Market Cap
- LNT 15.9B
- UTHR 13.8B
- IPO Year
- LNT N/A
- UTHR 1999
- Fundamental
- Price
- LNT $64.86
- UTHR $405.02
- Analyst Decision
- LNT Hold
- UTHR Strong Buy
- Analyst Count
- LNT 8
- UTHR 15
- Target Price
- LNT $64.63
- UTHR $449.13
- AVG Volume (30 Days)
- LNT 1.9M
- UTHR 897.9K
- Earning Date
- LNT 10-30-2025
- UTHR 10-29-2025
- Dividend Yield
- LNT 3.13%
- UTHR N/A
- EPS Growth
- LNT 32.39
- UTHR 17.94
- EPS
- LNT 3.24
- UTHR 25.63
- Revenue
- LNT $4,144,000,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- LNT $6.98
- UTHR $13.89
- Revenue Next Year
- LNT $4.84
- UTHR $5.68
- P/E Ratio
- LNT $20.04
- UTHR $15.71
- Revenue Growth
- LNT 4.59
- UTHR 17.62
- 52 Week Low
- LNT $56.08
- UTHR $266.98
- 52 Week High
- LNT $67.11
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- LNT 50.67
- UTHR 71.35
- Support Level
- LNT $63.62
- UTHR $395.00
- Resistance Level
- LNT $65.14
- UTHR $401.62
- Average True Range (ATR)
- LNT 0.76
- UTHR 13.35
- MACD
- LNT -0.15
- UTHR 6.12
- Stochastic Oscillator
- LNT 36.80
- UTHR 76.31
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.